Détail de l'auteur
Documents disponibles écrits par cet auteur (84)
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de recherche
Minimal manifestation status and prednisone withdrawal in the MGTX trial
Lee I, Kuo HC, Aban IB, et al.
Neurology, 2020
Guidelines on clinical presentation and management of non-dystrophic myotonias
Stunnenberg B, LoRusso S, Arnold WD, et al.
Muscle & Nerve, 2020
Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial
Pasnoor M, Heim AJ, Herbelin L, et al.
Kansas journal of medicine, 2020, 13, suppl 2, p 10
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
Green JD, Barohn RJ, Bartoccion E, et al.
BMJ Open, 2020, 10, 9
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
Campbell C, Barohn RJ, Bertini E, et al.
Journal of comparative effectiveness research, 2020
The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
Katz NK, Barohn RJ
Neuropharmacology, 2020
MRI Correlates with Electrical Impedance Myography in Facioscapulohumeral Muscular Dystrophy
Hamel J, Lee P, Glenn MD, et al.
Muscle & Nerve, 2019
Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part I: Traditional Agents
Farmakidis C, Dimachkie M, Pasnoor M, et al.
Muscle & Nerve, 2019
Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part II: New and Novel Agents.
Farmakidis C, Dimachkie M, Pasnoor M, et al.
Muscle & Nerve, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Hanna MG, Badrising UA, Benveniste O, et al.
The Lancet. Neurology, 2019, 18, 9, p 834
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis
Clifford KM, Clifford KM, Hobson-Webb LD, et al.
Muscle & Nerve, 2019, 59, 4, p 404
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study
Pena LDM, Barohn RJ, Byrne BJ, et al.
Neuromuscular disorders : NMD, 2019, 29, 3, p 167
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Wolfe GI, Kaminski HJ, Aban IB, et al.
The Lancet. Neurology, 2019, 18, 3, p 259
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Muppidi S, Utsugisawa K, Benatar M, et al.
Muscle & Nerve, 2019
Inclusion Body Myositis: Update on Pathogenesis and Treatment
Naddaf E, Barohn RJ, Dimachkie MM
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018, 15, 4, p 995
Congenital Myasthenic Syndromes: a Clinical and Treatment Approach
Farmakidis C, Farmakidis C, Pasnoor M, et al.
Current treatment options in neurology, 2018, 20, 9
Diagnosis of Myasthenia Gravis
Pasnoor M, Dimachkie MM, Farmakidis C, et al.
Neurologic clinics, 2018, 36, 2, p 261
Fifty Key Publications on Myasthenia Gravis and Related Disorders
Dimachkie MM, Barohn RJ
Neurologic clinics, 2018, 36, 2, p 13
Measuring Clinical Treatment Response in Myasthenia Gravis
Barnett C, Herbelin L, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 339
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies
Rivner MH, Pasnoor M, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 293
Treatment of Myasthenia Gravis
Farmakidis C, Pasnoor M, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 311
A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial
Crow RA, Hart KA, McDermott MP, et al.
Trials, 2018, 19, 1
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Lundberg IE, Tjärnlund A, Bottai M, et al.
Annals of the rheumatic diseases, 2017, 76, 12, p 1955
Developing standardized corticosteroid treatment for Duchenne muscular dystrophy
Guglieri M, Bushby K, McDermott MP, et al.
Contemporary clinical trials, 2017, 58, p 34
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing
Vander Heiden JA, Stathopoulos P, Zhou JQ, et al.
Journal of immunology (Baltimore, Md. : 1950), 2017, 198, 4, p 1460
